Transition From Apixaban (Eliquis) to Enoxaparin (Lovenox)
Apixaban should be discontinued and enoxaparin should be started at the time the next scheduled apixaban dose would have been given. [1][2] Bridging with a separate anticoagulant is generally not required during the transition between apixaban and low-molecular-weight heparin when continuous anticoagulant coverage is the goal. [2]
Medication Timing Algorithm
- Determine the next scheduled apixaban dose time. [1]
- Discontinue apixaban. [1]
- Initiate enoxaparin at the usual time of the next apixaban dose. [1][2]
Medication Selection Considerations
- Enoxaparin dosing depends on the indication (treatment vs prophylaxis) and renal function. [1]
- Apixaban-to-enoxaparin conversion timing does not replace indication-specific enoxaparin dosing. [1]
Monotherapy vs Overlap Strategy
- Overlap of apixaban with enoxaparin is not required for standard transitions when enoxaparin is started at the next scheduled apixaban dose time. [1][2]
Key Evidence Supporting This Recommendation
- A scientific statement on non–vitamin K antagonist oral anticoagulants in acute care and periprocedural settings recommends initiating parenteral anticoagulants at the usual time of the next scheduled apixaban dose when transitioning from apixaban to low-molecular-weight heparin. [1]
- A consensus guide on practical management of apixaban notes that switching between apixaban and LMWH can be performed at the time of the next scheduled dose because of similar rapid onset and predictable anticoagulant effect. [2]
Initiation Thresholds and Patient-Specific Modifiers
- Renal impairment can increase enoxaparin exposure and requires dose adjustment and careful monitoring per enoxaparin prescribing information. [1]
- Acute clinical events (such as new thrombosis or bleeding) and procedural timing can require an individualized periprocedural plan, which should be coordinated with the transition timing approach. [1]
Common Pitfalls to Avoid
- Starting enoxaparin too early can increase bleeding risk due to concurrent anticoagulant effect from the overlapping drug exposure period. [1]
- Delaying enoxaparin beyond the time the next apixaban dose would have been taken can create a period without intended anticoagulant coverage. [1][2]
Targets or Goals of Therapy During Transition
- The primary goal of the conversion is maintaining uninterrupted therapeutic anticoagulation by starting enoxaparin at the next scheduled apixaban dose time after apixaban discontinuation. [1][2]
Practical Implementation Checklist
- Confirm the next scheduled apixaban administration time. [1]
- Hold apixaban after the last dose and stop apixaban. [1]
- Administer the first enoxaparin dose at the next scheduled apixaban dose time. [1][2]
- Select enoxaparin dose based on indication and renal function. [1]